Biotech Industry Landscape – Executive Perspectives

Price range: $2,500.00 through $5,000.00

July 2026

Licensing Options

  • SINGLE-USER LICENSE

    A Single-User License allows access to an individual user.

  • ENTERPRISE-WIDE LICENSE

    An Enterprise-Wide License allows access to all employees and sites within an organization.

Report Overview

The lifeblood of most small to mid-size CROs are emerging biotech innovator companies. We’ve also witnessed over the past several years the large CROs creating dedicated units to support these smaller sponsor companies. Our Biotech Industry Landscape – Executive Perspectives report was developed to help the clinical development industry design strategies for their emerging biotech customers by understanding biotech executives’ perspectives and concerns.

This research unveils how senior leaders at small/emerging biotech companies “feel” about their company’s future, the industry’s future, and how service providers can impact their success.

 

What you will learn:

Financial Health & Drug Development Planning

  • Biotechs’ needs for near-term funding
  • Executives’ confidence in the health of the VC-funded biopharma industry
  • Trial delays due to funding issues
  • Studies negatively impacted by resourcing issues
  • Acceleration / Pulling back of near-term clinical development plans
  • Verbatim descriptions of important opportunities that could benefit biotechs
  • Expected changes to preclinical activities

Clinical Development Outsourcing & AI Use

  • Proportion of clinical development activities that are outsourced by biotechs
  • Importance rankings of various factors when biotechs are selecting a CRO for a Phase II study
  • Verbatim explanations of characteristics that pushed a CRO “over the top” in their last selection
  • Difficulty working with different partner types
  • Use of AI and its impact on efficiency in drug discovery and clinical trial operations

 

Respondents were required to pass several screening criteria to qualify and participate in this survey:

  • Must work at a biopharma company with less than $500M in annual R&D spend
  • Must have responsibility in at least one of several relevant areas such as Executive management / C-Suite, Medical / Scientific, R&D Management, Finance, or Clinical Operations
  • Must have assets in clinical development (Phase I-III)
  • Must work at a company headquartered in the United States
  • Must have an office location in the United States

Questions?

Our team is here to help.

For questions about syndicated report purchases, custom research solutions, or other billing-related topics, please contact sales@ISRreports.com.